Book 9 focuses on a new dementia type, LATE, mistaken as Alzheimer's disease until now.LATE stands for Limbic-predominant age-related TDP-43 encephalopathy, the protein buildup responsible for this dementia. This book is organic, like the series, meaning we never consider our books as finished. Science evolves, which is why our books go through continuous updates. Since LATE is a new dementia classification, we expect continuous further information to emerge. Watch Amazon alerts for potential digital updates. We provide free digital copies on all paperback purchases, so everybody receives free updates.

This up-to-date, superbly illustrated book is a practical guide to the effective use of neuroimaging in the patient with cognitive decline. It sets out the key clinical and imaging features of the various causes of dementia and directs the reader from clinical presentation to neuroimaging and on to an accurate diagnosis whenever possible. After an introductory chapter on the clinical background, the available "toolbox" of structural and functional neuroimaging techniques is reviewed in detail, including CT, MRI and advanced MR techniques, SPECT and PET, and image analysis methods. The imaging findings in normal ageing are then discussed, followed by a series of chapters that carefully present and analyze the key findings in patients with dementias. Throughout, a practical approach is adopted, geared specifically to the needs of clinicians (neurologists, radiologists, psychiatrists, geriatricians) working in the field of dementia, for whom this book will prove an invaluable resource.

Distils the most valuable discoveries in dementia research into clear, insightful chapters written by international experts.

A pioneering neuroscientist shows how the long-sought merger of brains with machines is about to become a paradigm-shifting reality Imagine living in a world where people use their computers, drive their cars, and communicate with one another simply by thinking. In this stunning and inspiring work, Duke University neuroscientist Miguel Nicolelis shares his revolutionary insights into how the brain creates thought and the human sense of self—and how this might be augmented by machines, so that the entire universe will be within our reach. Beyond Boundaries draws on Nicolelis's ground-breaking research with monkeys that he taught to control the movements of a robot located halfway around the globe by using brain signals alone. Nicolelis's work with primates has uncovered a new method for capturing brain function—by recording rich neuronal symphonies rather than the activity of single neurons. His lab is now paving the way for a new treatment for Parkinson's, silk-thin exoskeletons to grant mobility to the paralyzed, and breathtaking leaps in space exploration, global communication, manufacturing, and more. Beyond Boundaries promises to reshape our concept of the technological future, to a world filled with promise and hope.

Roughly one of every three Americans has some form of cardiovascular disease (CVD), including more than 70% of persons older than 75 years of age. Long associated with increased risk for mortality and disability, CVD is also a major risk factor for stroke and cerebrovascular disease. There has been growing consensus that CVD is also an important contributor to poor neurocognitive outcome in own right. Numerous studies now link CVD to accelerated cognitive decline, and structural and functional brain abnormalities, including neurodegnerative conditions in the elderly. While vascular dementia is the most obvious example of severe brain dysfunction directly tied to chronic vascular disease, evidence is also mounting that Alzheimer's disease may be linked to some of the same pathophysiological mechanisms that underlie cardiovascular disease. This book was written to provide up-to-date insight into these heart-brain connections and the neuropsychology of CVD. Highlights include: - Controversies in vascular dementia and vascular cognitive impairment (VCI) - Effects of aging on cerebral hemodynamics and autoregulation - How blood vessel function contributes to cognitive decline - Updates on the cognitive impact of cardiosurgical procedures - Neurocognitive aspects of heart failure - Neuropsychological evaluation of persons with CVD - Mechanisms by which neurological changes produce cardiac dysfunction - Recent findings in the structural and functional neuroimaging in CVD Both clinicians and researchers in neuropsychology, health psychology, cardiology, neurology, psychiatry, geriatrics and many others will find this book an important resource.

Due to the lack of secure, efficient, and patient-friendly therapies for neurodegenerative disorders, there is a rising demand for innovative approaches. Despite the limited number of nanocarriers approved for human use, they have demonstrated significant potential in preclinical and, in some instances, clinical trials. In alignment with this objective, the chapters of the book are structured to offer a comprehensive overview of recent advancements in medication and dosage form development, specifically emphasizing the nanoparticulate system for targeting the brain. This book aims to furnish readers with a thorough understanding of the clinical application of nanocarrier systems for treating neurodegenerative disorders, encompassing the latest developments, challenges, safety concerns, toxicity issues, regulatory considerations, prospects, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain will find valuable insights in this resource. Key Features Provides a comparative perspective of various nanocarrier systems, therefore facilitating the researcher's selection of appropriate nanoparticulate carriers Highlights the related restrictions of brain delivery and current available medicines Includes information on the advantages and disadvantages of various biomaterials utilized in the development of nanocarriers for brain targeting Emphasizes distinct facets of surface functionalization according to the brain area of interest Presents the current advances, preclinical and clinical development, and the future potential of multiple brain-targeting technologies

This monograph describes the progress in neuropathological HD research made during the last century, the neuropathological hallmarks of HD and their pathogenic relevance. Starting with the initial descriptions of the progressive degeneration of the striatum as one of the key events in HD, the worldwide practiced Vonsattel HD grading system of striatal neurodegeneration will be outlined. Correlating neuropathological data with results on the functional neuroanatomy of the human brain, subsequent chapters will highlight recent HD findings: the neuronal loss in the cerebral neo-and allocortex, the neurodegeneration of select thalamic nuclei, the affection of the cerebellar cortex and nuclei, the involvement of select brainstem nuclei, as well as the pathophysiological relevance of these pathologies for the clinical picture of HD. Finally, the potential pathophysiological role of neuronal huntingtin aggregations and the most important and enduring challenges of neuropathological HD research are discussed.

The failure of insulin signaling – a condition known as insulin resistance – is a key pathological feature of both type 2 diabetes (T2DM, systemic insulin resistance) and Alzheimer’s disease and related dementias (ADRDs, brain insulin resistance) and greatly contribute to their development. Considerable overlap has been identified in the risk factors, comorbidities and putative pathophysiological mechanisms of ADRDs and T2DM, thus proposing AD as type 3 diabetes.